Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00340509 · ClinicalTrials.gov registry record
A Genome-Wide Scan For Quantitative Trait Loci of Serum Bilirubin - A Framingham Study
A clinical trial of Genetics, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 1,888
- Enrollment target
- 1
- Study location
NCT00340509: Completed study of Genetics, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00340509 is a study of Genetics that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 1,888 participants, above the 943-participant average among 4 other Genetics trials with a reported enrollment target (100% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00340509, a study of Genetics, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 1,888 participants
- Enrollment target
- 1
- Study location
Study Summary
Studies have shown that there is a significant association between serum bilirubin concentrations and risk of coronary artery disease (CAD). So far, no linkage analysis in humans between serum bilirubin and DNA markers has been reported. The purpose of this protocol is to identify chromosome regions that contain quantitative trait loci (QTL) involved in serum bilirubin metabolism and bilirubin concentration. In the Framingham Study, a 10cM genome scan (about 400 markers) has been conducted in more than three hundred families. Serum bilirubin was measured in the first and second exams of the Framingham Offspring. These data provide us the opportunity to undertake linkage analyses to map QTL of serum bilirubin.
Conditions Studied
Study Locations (1)
Maryland
- National Heart, Lung and Blood Institute (NHLBI), 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,888 participants |
| Start Date | 2001-10-26 |
| Est. Completion | 2013-07-23 |
What the finished NCT00340509 record still lists
NCT00340509 is an observational study that tracks outcomes without assigning an intervention. Its 1,888 participants enrollment target places it among the larger protocols in the corpus, above the 943-participant average among 4 other Genetics trials with a reported enrollment target (100% higher).
The record links to 1 condition, with Genetics appearing as the primary indexed condition, and to 0 interventions.
NCT00340509 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00340509 about?
NCT00340509 is a clinical study titled "A Genome-Wide Scan For Quantitative Trait Loci of Serum Bilirubin - A Framingham Study". Studies have shown that there is a significant association between serum bilirubin concentrations and risk of coronary artery disease (CAD). So far, no linkage analysis in humans between serum bilirubin and DNA markers has been reported. The purpose of this protocol is to identify chromosome regions...
What is the current status of trial NCT00340509?
This trial is currently completed. The enrollment target is 1,888 participants. The study started on 2001-10-26. Estimated completion is 2013-07-23.
What conditions does trial NCT00340509 study?
This clinical trial studies the following conditions: Genetics.
Who is sponsoring clinical trial NCT00340509?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00340509 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetics
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phenotyping Genetic Risk for Type 2 Diabetes
RECRUITING · NA
-
TREC@TAMU Cancer Prevention Registry and Repository
RECRUITING
-
Study of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS
ACTIVE NOT RECRUITING · NA
-
Relationship of Skin Related SNP to Topical Skin Care Product
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06438640 · 1,881 participants · NA
Evaluating a Strategy to Improve Pre-Anesthesia Care Discussions (My Anesthesia Choice-Hip Fracture)
- NCT07308717 · 1,896 participants · Phase 4
Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- NCT05712200 · 1,900 participants · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI